Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.

Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores

Abstrato

In the Early Stages of the COVID-19 Epidemic, Weighing Evidence and First-Hand Experience

Levra S

Background: Severe acute respiratory pattern coronavirus 2(SARS- CoV- 2) is the causative agent of coronavirus complaint 2019(COVID- 19), which has fleetly come epidemic in Italy and other European countries. The complaint diapason ranges from asymptomatic/ mildly characteristic donations to acute respiratory failure. At the present time the absolute number of severe cases taking ventilator support is reaching or indeed surpassing the ferocious care unit bed capacity in the most affected regions and countries.

Objects: To narratively epitomize the available literature on the operation of COVID- 19 in order to combine current substantiation and frontline opinions and to give balanced answers to pressing clinical questions.

Sources: Inductive PubMed hunt for publications applicable to the content.

Content: The available literature and the authors' frontline- grounded opinion are epitomized in brief narrative answers to named clinical questions, with a conclusive statement handed for each answer.

Counteraccusations: Numerous off- marker antiviral andanti-inflammatory medicines are presently being administered to cases with COVID- 19. Physicians must be apprehensive that, as they aren't supported by highposition substantiation, these treatments may frequently be immorally maintainable only in those worsening cases doubtful to ameliorate only with probative care, and who cannot be enrolled onto randomized clinical trials. Access to well- designed randomized controlled trials should be expanded as much as possible because it's the most secure way to change for the better our approach to COVID- 19 cases.